Filtered By:
Condition: Ischemic Stroke
Therapy: Gene Therapy

This page shows you your search results in order of date.

Order by Relevance | Date

Total 32 results found since Jan 2013.

Gene therapy of adeno-associated virus (AAV) vectors in preclinical models of ischemic stroke
CNS Neurosci Ther. 2023 Aug 8. doi: 10.1111/cns.14392. Online ahead of print.ABSTRACTStroke has been associated with devastating clinical outcomes, with current treatment strategies proving largely ineffective. Therefore, there is a need to explore alternative treatment options for addressing post-stroke functional deficits. Gene therapy utilizing adeno-associated viruses (AAVs) as a critical gene vector delivering genes to the central nervous system (CNS) gene delivery has emerged as a promising approach for treating various CNS diseases. This review aims to provide an overview of the biological characteristics of AAV vec...
Source: CNS Neuroscience and Therapeutics - August 8, 2023 Category: Neuroscience Authors: Jing Wang Mengna Zhu Jingyi Sun Lina Feng Mingfeng Yang Baoliang Sun Leilei Mao Source Type: research

Deficiency of adenosine deaminase 2 (DADA2): Review
Best Pract Res Clin Rheumatol. 2023 Jun 15:101844. doi: 10.1016/j.berh.2023.101844. Online ahead of print.ABSTRACTThe deficiency of adenosine deaminase 2 (DADA2) is an autosomal recessive disease caused by loss-of-function (LOF) mutations in the ADA2 gene and was first described in 2014. Initially, it was described as vasculopathy/vasculitis that mostly affected infants and young children and closely resembled polyarteritis nodosa (PAN). Skin rash and ischemic/hemorrhagic stroke are predominant symptoms. However, the clinical spectrum of DADA2 has continued to expand since then. It has now been reported in adults as well. ...
Source: Cell Research - June 16, 2023 Category: Cytology Authors: Vikas Sharma Prateek Deo Aman Sharma Source Type: research

Genes, Vol. 13, Pages 978: Stroke and Etiopathogenesis: What Is Known?
Conclusion: We summarize the latest evidence and perspectives of ischemic stroke genetics that may be of interest to the physician and useful for day-to-day clinical work in terms of both prevention and treatment of ischemic stroke.
Source: Genes - May 30, 2022 Category: Genetics & Stem Cells Authors: Tiziana Ciarambino Pietro Crispino Erika Mastrolorenzo Antonello Viceconti Mauro Giordano Tags: Review Source Type: research

Genes, Vol. 13, Pages 144: Influence of Haptoglobin Polymorphism on Stroke in Sickle Cell Disease Patients
vain Doré This review outlines the current clinical research investigating how the haptoglobin (Hp) genetic polymorphism and stroke occurrence are implicated in sickle cell disease (SCD) pathophysiology. Hp is a blood serum glycoprotein responsible for binding and removing toxic free hemoglobin from the vasculature. The role of Hp in patients with SCD is critical in combating blood toxicity, inflammation, oxidative stress, and even stroke. Ischemic stroke occurs when a blocked vessel decreases oxygen delivery in the blood to cerebral tissue and is commonly associated with SCD. Due to the malformed red blood cells of s...
Source: Genes - January 14, 2022 Category: Genetics & Stem Cells Authors: Olivia Edwards Alicia Burris Josh Lua Diana J. Wilkie Miriam O. Ezenwa Sylvain Dor é Tags: Review Source Type: research

Genes, Vol. 13, Pages 48: Ischemic Stroke Genetics: What Is New and How to Apply It in Clinical Practice?
Jatužis The etiology of ischemic stroke is multifactorial. Although receiving less emphasis, genetic causes make a significant contribution to ischemic stroke genesis, especially in early-onset stroke. Several stroke classification systems based on genetic information corresponding to various stroke phenotypes were proposed. Twin and family history studies, as well as candidate gene approach, are common methods to discover genetic causes of stroke, however, both have their own limitations. Genome-wide association studies and next generation sequencing are more efficient, promising and increasingly used for daily diagn...
Source: Genes - December 24, 2021 Category: Genetics & Stem Cells Authors: Aleksandra Ekkert Aleksandra Šliachtenko Julija Grigait ė Birut ė Burnytė Algirdas Utkus Dalius Jatu žis Tags: Review Source Type: research

Clinical features, pathogenesis, and management of stroke-like episodes due to MELAS
AbstractMitochondrial encephalomyopathy with lactic acidosis and stroke-like episodes (MELAS) is a disease that should be considered as a differential diagnosis to acute ischemic stroke taking into account its onset pattern and neurological symptoms, which are similar to those of an ischemic stroke. Technological advancements in neuroimaging modalities have greatly facilitated differential diagnosis between stroke and MELAS on diagnostic imaging. Stroke-like episodes in  MELAS have the following features: (1) symptoms are neurolocalized according to lesion site; (2) epileptic seizures are often present; (3) lesion distri...
Source: Metabolic Brain Disease - November 15, 2021 Category: Neurology Source Type: research

Mesenchymal Stromal Cells (MSCs): a promising tool for cell-based angiogenic therapy
Curr Gene Ther. 2021 Sep 16. doi: 10.2174/1566523221666210917114353. Online ahead of print.ABSTRACTThe Mesenchymal stromal cells (MSCs) are a diverse subset of adult multipotent precursors, known for their potential therapeutic properties in regenerative medicine mainly sustained by paracrine effects, through secretion of a variety of biologically active molecules. MSC secretome includes a wide range of soluble protein factors, composed of growth factors and cytokines, and vesicular components, which transfer proteins and genetic material modulating the host microenvironment. In particular, MSC-derived secretome mediates t...
Source: Current Gene Therapy - September 17, 2021 Category: Genetics & Stem Cells Authors: Cristiana Ulpiano Cl áudia L da Silva Gabriel A Monteiro Source Type: research

Clinical features, pathogenesis, and management of stroke-like episodes due to MELAS
AbstractMitochondrial encephalomyopathy with lactic acidosis and stroke-like episodes (MELAS) is a disease that should be considered as a differential diagnosis to acute ischemic stroke taking into account its onset pattern and neurological symptoms, which are similar to those of an ischemic stroke. Technological advancements in neuroimaging modalities have greatly facilitated differential diagnosis between stroke and MELAS on diagnostic imaging. Stroke-like episodes in  MELAS have the following features: (1) symptoms are neurolocalized according to lesion site; (2) epileptic seizures are often present; (3) lesion distri...
Source: Metabolic Brain Disease - June 12, 2021 Category: Neurology Source Type: research

Nanoparticle-Based Gene Therapy Intervention for Stroke Treatment: a Systematic Review.
In conclusion, due to the inability of brain regeneration and the importance of genes in stroke-related complications, gene therapy seems to be a suitable treatment strategy. The use of suitable nanoparticles for transportation ensures the efficiency and usefulness of this method. PMID: 33045966 [PubMed - as supplied by publisher]
Source: Current Gene Therapy - October 12, 2020 Category: Genetics & Stem Cells Authors: Ghasemi S, Alavian K, Alavian F Tags: Curr Gene Ther Source Type: research

Long-term follow-up and safety assessment of angiogenic gene therapy trial VIF-CAD: Transcatheter intramyocardial administration of a bicistronic plasmid expressing VEGF-A165/bFGF cDNA for the treatment of refractory coronary artery disease
This study presents the results of over 10-year (median 133 months, range 95–149) safety follow-up of VIF-CAD patients. Overall, 12 (36.4%) patients died in VIF and 8 (42.1%) in Placebo group (P = .68). Cardiovascular mortality was 12/33 (36.4%) in the VIF group and 6/19 (31.6%) in Placebo group (P = .73). Two Placebo patients died due to malignancies, but no VIF patients (P = .17). The Kaplan–Meier curves of combined endpoint: cardiovascular mortality, myocardial infarction and stroke were similar for both patient groups (P = .71). Odds ratio of Placebo group increasing (re...
Source: American Heart Journal - June 20, 2019 Category: Cardiology Source Type: research

Connecting Metainflammation and Neuroinflammation Through the PTN-MK-RPTP β/ζ Axis: Relevance in Therapeutic Development
Conclusion The expression of the components of the PTN-MK-RPTPβ/ζ axis in immune cells and in inflammatory diseases suggests important roles for this axis in inflammation. Pleiotrophin has been recently identified as a limiting factor of metainflammation, a chronic pathological state that contributes to neuroinflammation and neurodegeneration. Pleiotrophin also seems to potentiate acute neuroinflammation independently of the inflammatory stimulus while MK seems to play different -even opposite- roles in acute neuroinflammation depending on the stimulus. Which are the functions of MK and PTN in chronic neuroi...
Source: Frontiers in Pharmacology - April 11, 2019 Category: Drugs & Pharmacology Source Type: research

Combined Gene Therapy to Reduce the Neuronal Damage in the Mouse Model of Focal Ischemic Injury
AbstractResearch into stroke is driven by frustration over the limited available therapeutics. Targeting a single aspect of this multifactorial disease contributes to the therapeutic boundaries. To overcome this, we devised a novel multifactorial-cocktail treatment, using lentiviruses encoding excitatory amino acid transporter 2 (EAAT2(, glutamate dehydrogenase 2 (GDH2), and nuclear factor E2-related factor 2 (Nrf2) genes, that acts synergistically to address the effected excito-oxidative axis. Here, we used the vasoconstrictor endothelin-1 (ET-1) to induce focal ischemic injury in mice by direct injection into the striatu...
Source: Journal of Molecular Neuroscience - October 1, 2018 Category: Neuroscience Source Type: research